Essex Bio-Technology Limited provided unaudited consolidated earnings guidance for the five months ended May 31, 2020. For the five months, the company expected profit of the Group for the period has significantly decreased by approximately 70% as compared to the corresponding period in 2019. The decrease is primarily attributable to the governmental restrictions in place during the Period in a number of provinces and municipalities in the People's Republic of China (the "PRC") to curb the spread of the novel coronavirus (COVID-19), which significantly disrupted the clinical operations of hospitals in the PRC and have prevented non-emergency patients visiting hospitals and outpatient clinics, as mentioned in the announcement of the company dated 17 February 2020 and the 2019 annual results announcement of the company dated 17 March 2020. As at the date of this announcement, the clinical operations of hospitals and outpatient clinics have not been fully back to its normal level prior to the outbreak of COVID-19, although significant improvement is seen in June 2020 as compared to the Period.